This is the authors' abstract. We don't add key points for this paper.
Interim analyses for group-sequential decision-making are prevalent in clinical trials. Methodology is well established and has been routinely implemented over the last decades. Still, confusions and uncertainties on aspects of how to operationalize and interpret interim analyses exist for many stakeholders. In this paper, a team of statisticians from the pharmaceutical industry, academia, and regulatory agencies provide a multi-stakeholder perspective on the key concepts behind interim analyses, with the aim to introduce standard terminology to mitigate misunderstandings and facilitate clearer discussions.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Asikanius et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: